文献速递垂体与肾上腺疾病

人垂体神经内分泌肿瘤来源类器官的建立及其在药物筛选中的初步应用

Establishment of Human Pituitary Neuroendocrine Tumor Derived Organoid and Its Pilot Application for Drug Screening.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该研究于2019年7月至2022年5月在中山大学肿瘤防治中心收集32例人垂体神经内分泌肿瘤(PitNET)标本,采用优化培养方案建立患者来源类器官(PDO)。PDO总体建立成功率为87.5%,无功能型PitNET来源类器官成功率(22/23,95.7%)高于功能型(6/9,66.7%),并保留亲本肿瘤的组织学、基因组及微环境异质性特征,在药物测试中呈现亚型特异性反应。

要点

  • 32例PitNET标本建立PDO,总体成功率为87.5%。
  • 无功能型PitNET来源类器官成功率为95.7%(22/23),功能型为66.7%(6/9)。
  • PDO保留亲本肿瘤的细胞结构、亚型特异性神经内分泌特征、突变特征及肿瘤微环境异质性。

核心结论

  • 建立的PDO保留亲本肿瘤的典型特征,在为难治性PitNET创新个性化治疗方面具有转化意义。

研究设计与样本

  • 研究于2019年7月至2022年5月在中山大学肿瘤防治中心收集32例经病理确诊的PitNET患者标本,采用优化培养方案建立患者来源类器官(PDO)。
  • 采用组织学染色和全外显子组测序确认PDO的病理和基因组特征,并对PDO进行药物反应检测。

主要发现

  • PDO可从多种类型PitNET标本中成功建立,总体成功率为87.5%。
  • 无功能型PitNET来源类器官成功率为95.7%(22/23),高于功能型PitNET来源类器官的66.7%(6/9)。
  • 观察到PDO保留亲本肿瘤的细胞结构、亚型特异性神经内分泌特征、突变特征及肿瘤微环境异质性。
  • 不同PitNET亚型患者来源的类器官在药物测试中呈现不同的反应特征。
  • 通过组织学、基因组和微环境异质性一致性检测验证亲本肿瘤关键特征后,证明PDO在测试个体药物方面具有预测价值。

临床怎么用

  • 作者认为,所建立的PDO保留亲本肿瘤典型特征,在为难治性PitNET创新个性化治疗方面具有转化意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Precision medicine for pituitary neuroendocrine tumors (PitNETs) is limited by the lack of reliable research models. OBJECTIVE: To generate patient-derived organoids (PDOs), which could serve as a platform for personalized drug screening for PitNET patients. DESIGN: From July 2019 to May 2022, a total of 32 human PitNET specimens were collected for the establishment of organoids with an optimized culture protocol. SETTING: This study was conducted at Sun Yat-Sen University Cancer Center. PATIENTS: PitNET patients who were pathologically confirmed were enrolled in this study. INTERVENTIONS: Histological staining and whole-exome sequencing were utilized to confirm the pathologic and genomic features of PDOs. A drug response assay on PDOs was also performed. MAIN OUTCOME MEASURES: PDOs retained key genetic and morphological features of their parental tumors. RESULTS: PDOs were successfully established from various types of PitNET samples with an overall success rate of 87.5%. Clinical nonfunctioning PitNETs-derived organoids (22/23, 95.7%) showed a higher likelihood of successful generation compared to those from functioning PitNETs (6/9, 66.7%). Preservation of cellular structure, subtype-specific neuroendocrine profiles, mutational features, and tumor microenvironment heterogeneity from parental tumors was observed. A distinctive response profile in drug tests was observed among the organoids from patients with different subtypes of PitNETs. With the validation of key characteristics from parental tumors in histological, genomic, and microenvironment heterogeneity consistency assays, we demonstrated the predictive value of the PDOs in testing individual drugs. CONCLUSION: The established PDOs, retaining typical features of parental tumors, indicate a translational significance in innovating personalized treatment for refractory PitNETs.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Cui R, Duan H, Hu W, et al. Establishment of Human Pituitary Neuroendocrine Tumor Derived Organoid and Its Pilot Application for Drug Screening. J Clin Endocrinol Metab. 2025. PMID: 38656317. doi:10.1210/clinem/dgae228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。